Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

34results about How to "Lower LDL-C levels" patented technology

Application of copperleaf herb aqueous extract in preparation of weight-losing and lipid-lowering medicines or weight-losing and lipid-lowering health-care products

InactiveCN112057491ASignificant weight loss and fat-lowering effectImproves antioxidant activityMetabolism disorderDigestive systemRotary evaporatorLipid oxidation
The invention discloses application of a copperleaf herb aqueous extract in preparation of weight-losing and lipid-lowering medicines or weight-losing and lipid-lowering health-care products. A preparation method of the copperleaf herb aqueous extract includes the steps that whole copperleaf herb is collected, cleaned, and dried; the copperleaf herb is crushed to obtain copperleaf herb dry powder;the copperleaf herb dry powder is added into an extraction tank, then pure water is added, and then soaking, decocting, and filtering are conducted; filtrate is collected, filtered solids is decoctedwith the pure water again, filtering is conducted, and the filtrate is collected; the pure water is finally added into the filtered solids, decocting and filtering are conducted, and the filtrate iscollected; and the filtrate from the filtration for three times is combined and concentrated in a rotary evaporator, and a copperleaf herb aqueous extract original liquid medicine is obtained. In-vivoanimal tests show that the copperleaf herb aqueous extract has obvious weight-losing and lipid-lowering effects; the copperleaf herb aqueous extract can also inhibit the contents of TC, TG and LDL-Cin serum of mice, increase the activity of SOD enzymes in livers of the mice, and reduce the content of MDA, so that the antioxidant activity of organisms is high, lipid oxidation is reduced, liver injury is relieved, and the effect of protecting the organisms is achieved.
Owner:SOUTHWEAT UNIV OF SCI & TECH

Hypoglycemic active part of osmanthus fragrans, preparation method and application thereof

InactiveCN101664423ASignificant antioxidantSignificant hypolipidemic effectMetabolism disorderPlant ingredientsAutoimmune responsesEthyl acetate
The invention relates to a hypoglycemic active part of osmanthus fragrans, a preparation method and application thereof, and application of the osmanthus fragrans in reducing blood fat, wherein the hypoglycemic active part of the omanthus fragrans is that the osmanthus osmanthus is extracted by petroleum ether, ethyl acetate and normal butanol to prepare petroleum ether, ethyl acetate and normal butanol extracts respectively, wherein the ethyl acetate extract is further separated to prepare triterpene from osmanthus fragrans. An effective component, namely the triterpene from osmanthus fragrans, can be used for preparing natural hypolipidemic and anti-oxidant medicaments; and the osmanthus fragrans of the invention and the effective component thereof, namely the triterpene from osmanthus fragrans, are used for preparing health products for the application of the prevention and adjuvant therapy of hyperlipemia. In vivo animal experiments prove that the triterpene from osmanthus fragranshas the remarkable effect of reducing the level of TC, TG and LDL-C in serum of mice with the hyperlipemia, and also has the effect of reducing MDA and increasing the activity of SOD at the same time. Therefore, the osmanthus fragrans not only can reduce the blood lipid level in the serum by improving the autoimmunity, but also can reduce the blood fat by improving the in vivo antioxidant mechanism.
Owner:HENAN UNIVERSITY

Exosome of LDLR mutant, preparation method of exosome, and application of exosome in preparing drug against hyperlipidaemia

The invention discloses an exosome of an LDLR mutant, a preparation method of the exosome, and an application of the exosome in preparing drug against hyperlipidaemia, and relates to the technical field of drugs for treating dyslipidemia. The preparation method comprises the following steps: inoculating a medium containing fetal bovine serum with hepatocytes, transfecting the hepatocytes with adenoviruses over-expressing a low-density lipoprotein receptor gene mutant that is terminating mutation caused by mutation of a single base in an O-linked sugar chain domain of the low-density lipoprotein receptor gene; then replacing the serum-free medium and continuously conducting culturing after transfection, and collecting supernatant; centrifuging the supernatant to remove floating living cells, thereby obtaining the supernatant containing the exosome; and condutcing separating and purifying to obtain the cell exosome over-pressing the low-density lipoprotein receptor gene mutant. The exosome of the present invention is a natural vector produced by an endogenous cell. The exosome is used as a transport vector, and has the unique advantages of low immunogenicity, high transport efficiency, good stability, high targetability and ability to pass the blood-brain barrier.
Owner:HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products